Regulation of placental amino acid transporter activity by mammalian target of rapamycin.
The activity of placental amino acid transporters is decreased in intrauterine growth restriction (IUGR), but the underlying regulatory mechanisms have not been established. Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway has been shown to decrease the activity of the system L amino acid transporter in human placental villous fragments, and placental mTOR activity is decreased in IUGR. In the present study, we used cultured primary trophoblast cells to study mTOR regulation of placental amino acid transporters in more detail and to test the hypothesis that mTOR alters amino acid transport activity by changes in transporter expression. Inhibition of mTOR by rapamycin significantly reduced the activity of system A (-17%), system L (-28%), and taurine (-40%) amino acid transporters. mRNA expression of isoforms of the three amino acid transporter systems in response to mTOR inhibition was measured using quantitative real-time PCR. mRNA expression of l-type amino acid transporter 1 (LAT1; a system L isoform) and taurine transporter was reduced by 13% and 50%, respectively; however, mTOR inhibition did not alter the mRNA expression of system A isoforms (sodium-coupled neutral amino acid transporter-1, -2, and -4), LAT2, or 4F2hc. Rapamycin treatment did not significantly affect the protein expression of any of the transporter isoforms. We conclude that mTOR signaling regulates the activity of key placental amino acid transporters and that this effect is not due to a decrease in total protein expression. These data suggest that mTOR regulates placental amino acid transporters by posttranslational modifications or by affecting transporter translocation to the plasma membrane.
Roos
S
S
Perinatal Center, Department of Physiology, Institute of Neuroscience and Physiology, University of Gothenburg, PO Box 432, Gothenburg SE-405 30, Sweden. sara.roos@gu.se
Kanai
Y
Y
Prasad
P D
PD
Powell
T L
TL
Jansson
T
T
D026924:Amino Acid Transport System A / Q000378:metabolism; D027062:Amino Acid Transport System L / Q000378:metabolism; D026905:Amino Acid Transport Systems / Q000235:genetics / Q000378:metabolism*; D017209:Apoptosis; D002470:Cell Survival; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism; D011247:Pregnancy; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D021381:Protein Transport; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D013997:Time Factors; D014327:Trophoblasts / Q000187:drug effects / Q000378:metabolism*; D000099247:Taurine Transporters
D026924:Amino Acid Transport System A; D027062:Amino Acid Transport System L; D026905:Amino Acid Transport Systems; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D011494:Protein Kinases; D012333:RNA, Messenger; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; D000099247:Taurine Transporters; C546842:MTOR protein, human